Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -37.0% | +69.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +22.4% | +11.2% (5yr)2 analysts |
| Net Income | N/A | N/A | -40.6% | +69.4% (5yr)2 analysts |
| EBIT | N/A | N/A | +4.6% | +24.5% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.4% over three years. Forward estimates point to EPS at +69.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
BioMarin Pharmaceutical Inc. NASDAQ:BMRN | $11.09B | $57.23 | Undervalued | 39.4 | +13.42% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -63.23% |
Pharvaris N.V. NASDAQ:PHVS | $2.34B | $33.36 | Not rated | -11.0 | +31.62% |
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | $1.96B | $7.61 | Undervalued | -4.8 | +4.29% |
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -7.71% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +15.35% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.63% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -28.23% |
ProQR Therapeutics N.V. NASDAQ:PRQR | $198.98M | $1.41 | Not rated | -3.8 | -47.12% |
Continue the stock analysis
Jump to another research area for this company.